HOME >> BIOLOGY >> NEWS
Sandia Discovery About Protein May Help Clean Up Pollutants, Find Cures For Diseases

emes were conserved, that is, the same shape is found in multiple proteins from different species."

Another new concept that Shelnutt's research has revealed is that many hemes change shape and go from one distortion to another as they perform their work. For example, when a certain protein binds with oxygen, the heme in the protein changes shape, loosing its ruffling distortion. This causes the protein itself to change shape, turning off a biochemical reaction called nitrogen fixation. Then, when oxygen is no longer around, the heme ruffles once again, and nitrogen fixation is switched back on.

"Sometimes, though, the heme doesn't change at all," Shelnutt says. "It just depends on the job that needs to be done."

Shelnutt's interest in protein analysis and hemes dates back about ten years when he was researching the prospect of engineering molecules to, for example, change gaseous fuel to liquid fuel. Having a history of working with heme proteins at Bell Labs, he wondered if a protein could alter the heme's shape and function as well.

Shelnutt believes that his discovery might lead to changes in the way diseases are treated in the future or for other scientific advances. In collaboration with a French scientist, he is already using his knowledge to develop new anti-inflammatory drugs.

Another possibility is to understand how hemes from another protein Shelnutt is working with convert sulfites or nitrites -- common pollutants -- into hydrogen sulfide or ammonia. Then, analogous arrangements of hemes could be chemically engineered, produced in batches, and released to clean up waste sites.

"The revelation that heme shape is correlated to a protein's function is so new that we don't yet know where this knowledge can take us," Shelnutt says. "We have a new key to better understand life and now we have to figure out what to do with it."


'"/>

Contact: Chris Burroughs
coburro@sandia.gov
505-844-0948
DOE/Sandia National Laboratories
26-Apr-1999


Page: 1 2 3

Related biology news :

1. Sandia experiments may reduce possibility of future water wars
2. $6 million appropriation to focus Sandia research on drinking water desalination, removal of arsenic
3. Sandia-aided method to heal wounded and diseased achieves US government acceptance
4. Sandia pursues biotechnology as new technology focus area
5. Sandia-developed formulation among products selected to help rid U.S. facilities of anthrax
6. Sandia portable chemical sensor system promises new way of detecting underwater explosives
7. Sandia-developed remote sensor expected to analyze gases up to two miles away
8. Sandia, University Of Montana Researchers Try Training Bees To Find Buried Landmines
9. Sandia Decontamination Foam May Be Tomorrows Best First Response In A Chem-Bio Attack
10. Improved Oxygen Bath To Heal Wounds, Lessen Number Of Amputations: Sandia To Sign Agreement With Numotech To Help Create Home-Use Healing Facility
11. Tracking Hepatitis C: Health Project Demos Worldwide Early-Warning System For Disease Outbreaks; Sandia Tests Disease-Tracking Approach

Post Your Comments:
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30
Cached News: